Dr. Mitchell Kamrava, MD

Dr. Kamrava practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Kamrava's NPI, 1982806097, was assigned on June 1, 2007. Dr. Kamrava graduated from UC San Diego School of Medicine in 2005. Dr. Kamrava holds California license A99555.

Dr. Kamrava's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Kamrava's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. Dr. Kamrava is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kamrava practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Kamrava's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Kamrava is board certified in radiation oncology by the American Board of Radiology. Dr. Kamrava is licensed in California.

Dmand AI lists anal cancer radiation, bone cancer radiation, cancer radiation-upper GI, cervical cancer radiation, colorectal cancer radiation, pancreatic cancer radiation, prostate cancer radiation and uterine cancer radiation among the conditions Dr. Kamrava treats.

CMS data shows 1,521 Medicare services from Dr. Kamrava across 16 procedure codes in 2024, for 221 Medicare patients. Medicare paid $113,517 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 221 Medicare patients who saw Dr. Kamrava in 2024. The largest group is 65 to 74, with 102 patients. 75% of them have cancer, and 75% have high blood pressure. 27% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kamrava's median patient age at 73, with 47% women.

In 2024, Dr. Kamrava wrote 56 Medicare Part D claims for 20 patients. 80% of them were for generic drugs. CMS names the drug for 17 of them, across 1 drug with 11 or more claims each, at $296 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Kamrava for performance year 2024, reported as part of a group. Dr. Kamrava accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kamrava as offering telehealth.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 121 papers to Dr. Kamrava, published from 2007 to 2025. 2020 was the busiest year, with 14. The most frequent topics are Brachytherapy, Radiotherapy Dosage and Uterine Cervical Neoplasms. Dr. Kamrava has published most often in Brachytherapy. Dr. Kamrava's most frequent co-authors are Katelyn Mae Atkins, MD, Sushil Beriwal, MD and Catheryn M. Yashar, MD.

Dmand AI links Dr. Kamrava to 7 clinical trials. 3 are still active or recruiting. Conditions studied include Cardiotoxicity, Lymphatic Metastasis and Sarcoma. Jonsson Comprehensive Cancer Center sponsors the most, 2.

CMS Open Payments shows 16 general payments to Dr. Kamrava from 8 drug and device companies from 2024 to 2025. Consulting fees make up the largest share, 92% of the total. GT Medical Technologies, Inc paid the most, $15,810.

Dmand AI lists 9 awards for Dr. Kamrava, most recently CMS Stage 1 EHR in 2013. Dr. Kamrava serves on UCLA Institutional Review Board and Gynecologic Oncology Group.

Dr. Kamrava graduated from UC San Diego School of Medicine in 2005.

Dr. Kamrava is in network with 13 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.